COVID-19 Modifications for Remote Teleassessment and Teletraining of a Complementary Alternative Medicine Intervention for People With Multiple Sclerosis: Protocol for a Randomized Controlled Trial.
COVID-19
disability
multiple sclerosis
physical activity
tele-exercise
telehealth
telerehabilitation
teletraining
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
03 Jul 2020
03 Jul 2020
Historique:
received:
04
05
2020
accepted:
13
06
2020
revised:
11
06
2020
pubmed:
17
6
2020
medline:
17
6
2020
entrez:
17
6
2020
Statut:
epublish
Résumé
Access to comprehensive exercise and rehabilitation services for people with multiple sclerosis (MS) remains a major challenge, especially in rural, low-income areas. Hence, the Tele-Exercise and Multiple Sclerosis (TEAMS) study aims to provide patient-centered, coordinated care by implementing a 12-week complementary and alternative medicine (CAM) intervention for adults with MS. However, due to the societal impact of coronavirus disease (COVID-19) in mid-March 2020, the University of Alabama at Birmingham announced a limited business model halting all nonessential research requiring on-site visits, which includes the TEAMS study. In compliance with the shelter-in-place policy and quarantine guidance, a modified testing and training protocol was developed to allow participants to continue the study. The modified protocol, which replaces on-site data collection and training procedures, includes a teleassessment package (computer tablet, blood pressure cuff, hand dynamometer, mini disc cone, measuring tape, an 8" step, and a large-print 8" × 11" paper with ruler metrics and wall-safe tape) and a virtual meeting platform for synchronous interactive training between the therapist and the participant. The teleassessment measures include resting blood pressure and heart rate, grip strength, Five Times Sit to Stand, Timed Up & Go, and the Berg Balance Scale. The teletraining component includes 20 sessions of synchronous training sessions of dual tasking, yoga, and Pilates exercises designed and customized for a range of functional levels. Teletraining lasts 12 weeks and participants are instructed to continue exercising for a posttraining period of 9 months. The protocol modifications were supported with supplemental funding (from the Patient-Centered Outcomes Research Institute) and approved by the University Institutional Review Board for Human Use. At the time nonessential research visits were halted by the university, there were 759 people enrolled and baseline tested, accounting for 92.5% of our baseline testing completion target (N=820). Specifically, 325 participants completed the 12-week intervention and follow-up testing visits, and 289 participants needed to complete either the intervention or follow-up assessments. A modified analysis plan will include sensitivity analyses to ensure the robustness of the study results in the presence of uncertainty and protocol deviations. Study results are projected to be published in 2021. This modified remote teleassessment/teletraining protocol will impact a large number of participants with MS who would otherwise have been discontinued from the study. ClinicalTrials.gov NCT03117881; https://clinicaltrials.gov/ct2/show/NCT03117881. DERR1-10.2196/18415.
Sections du résumé
BACKGROUND
BACKGROUND
Access to comprehensive exercise and rehabilitation services for people with multiple sclerosis (MS) remains a major challenge, especially in rural, low-income areas. Hence, the Tele-Exercise and Multiple Sclerosis (TEAMS) study aims to provide patient-centered, coordinated care by implementing a 12-week complementary and alternative medicine (CAM) intervention for adults with MS. However, due to the societal impact of coronavirus disease (COVID-19) in mid-March 2020, the University of Alabama at Birmingham announced a limited business model halting all nonessential research requiring on-site visits, which includes the TEAMS study.
OBJECTIVE
OBJECTIVE
In compliance with the shelter-in-place policy and quarantine guidance, a modified testing and training protocol was developed to allow participants to continue the study.
METHODS
METHODS
The modified protocol, which replaces on-site data collection and training procedures, includes a teleassessment package (computer tablet, blood pressure cuff, hand dynamometer, mini disc cone, measuring tape, an 8" step, and a large-print 8" × 11" paper with ruler metrics and wall-safe tape) and a virtual meeting platform for synchronous interactive training between the therapist and the participant. The teleassessment measures include resting blood pressure and heart rate, grip strength, Five Times Sit to Stand, Timed Up & Go, and the Berg Balance Scale. The teletraining component includes 20 sessions of synchronous training sessions of dual tasking, yoga, and Pilates exercises designed and customized for a range of functional levels. Teletraining lasts 12 weeks and participants are instructed to continue exercising for a posttraining period of 9 months.
RESULTS
RESULTS
The protocol modifications were supported with supplemental funding (from the Patient-Centered Outcomes Research Institute) and approved by the University Institutional Review Board for Human Use. At the time nonessential research visits were halted by the university, there were 759 people enrolled and baseline tested, accounting for 92.5% of our baseline testing completion target (N=820). Specifically, 325 participants completed the 12-week intervention and follow-up testing visits, and 289 participants needed to complete either the intervention or follow-up assessments. A modified analysis plan will include sensitivity analyses to ensure the robustness of the study results in the presence of uncertainty and protocol deviations. Study results are projected to be published in 2021.
CONCLUSIONS
CONCLUSIONS
This modified remote teleassessment/teletraining protocol will impact a large number of participants with MS who would otherwise have been discontinued from the study.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03117881; https://clinicaltrials.gov/ct2/show/NCT03117881.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/18415.
Identifiants
pubmed: 32540838
pii: v9i7e18415
doi: 10.2196/18415
pmc: PMC7337611
doi:
Banques de données
ClinicalTrials.gov
['NCT03117881']
Types de publication
Journal Article
Langues
eng
Pagination
e18415Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK056336
Pays : United States
Informations de copyright
©Byron Lai, Chia-Ying Chiu, Emily Pounds, Tracy Tracy, Tapan Mehta, Hui-Ju Young, Emily Riser, James Rimmer. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 03.07.2020.
Références
Mult Scler. 2008 Jan;14(1):129-35
pubmed: 17881388
Arch Phys Med Rehabil. 2017 Apr;98(4):659-664.e1
pubmed: 27894732
Mult Scler Relat Disord. 2019 Nov;36:101258
pubmed: 31472419
J Psychosom Res. 2014 Jun;76(6):465-71
pubmed: 24840141
JMIR Mhealth Uhealth. 2018 May 24;6(5):e10181
pubmed: 29798832
Mult Scler Relat Disord. 2015 Jul;4(4):358-69
pubmed: 26195057
BMC Neurol. 2020 Mar 13;20(1):93
pubmed: 32169035
Eur J Phys Rehabil Med. 2017 Dec;53(6):841-847
pubmed: 28290192
J Physiother. 2013 Jun;59(2):93-9
pubmed: 23663794
J Med Internet Res. 2011 Mar 10;13(1):e30
pubmed: 21393123
Disabil Rehabil. 2018 Feb;40(4):373-387
pubmed: 27973919
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
Int J Rehabil Res. 2012 Mar;35(1):69-74
pubmed: 22315143
NeuroRehabilitation. 2012;30(4):369-74
pubmed: 22672953
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 02;5(6):e505
pubmed: 30775409
Arch Phys Med Rehabil. 2016 Sep;97(9):1564-1572
pubmed: 26896750
Contemp Clin Trials. 2018 Aug;71:186-193
pubmed: 29859267
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Telemed Telecare. 2003;9(6):311-20
pubmed: 14680514
Disabil Rehabil. 2007 Dec 30;29(24):1920-5
pubmed: 17852286
Disabil Rehabil. 2006 Jun 30;28(12):789-95
pubmed: 16754576
Arch Phys Med Rehabil. 2016 Jul;97(7):1072-7
pubmed: 26944709
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040